High adherence to national IPC guidelines as key to sustainable VRE control in Swiss hospitals: a cross-sectional survey.
Acute care
Admission screening
Contact precautions
Infection prevention and control
Outbreak
Surveillance
Vancomycin resistant Enterococcus faecium
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
28 01 2022
28 01 2022
Historique:
received:
28
09
2021
accepted:
22
12
2021
entrez:
29
1
2022
pubmed:
30
1
2022
medline:
12
2
2022
Statut:
epublish
Résumé
Vancomycin resistant enterococci (VRE) are on the rise in many European hospitals. In 2018, Switzerland experienced its largest nosocomial VRE outbreak. The national center for infection prevention (Swissnoso) elaborated recommendations for controlling this outbreak and published guidelines to prevent epidemic and endemic VRE spread. The primary goal of this study was to evaluate adherence to this new guideline and its potential impact on the VRE epidemiology in Swiss acute care hospitals. In March 2020, Swissnoso distributed a survey among all Swiss acute care hospitals. The level of adherence as well as changes of infection prevention and control (IPC) strategies in the years 2018 and 2019 after publication of the national guidelines were asked along with an inventory on VRE surveillance and outbreaks. Data of 97/146 (66%) participants were available, representing 81.6% of all acute care beds operated in Switzerland in 2019. The vast majority-72/81 (88%) responding hospitals-have entirely or largely adopted our new national guideline. 38/51 (74.5%) hospitals which experienced VRE cases were significantly more likely to have changed their IPC strategies than those 19/38 (50%) hospitals without VRE cases p = 0.017). The new IPC guidelines included (1) introduction of targeted admission screening in 89.5%, (2) screening of close contacts of VRE cases in 56%, and (3) contact precaution for suspected VRE cases 58% of these hospitals. 52 (54%) hospitals reported 569 new VRE cases in 2018 including 14 bacteremia, and 472 new cases in 2019 with 10 bacteremia. The ten largest outbreaks encountered between 2018 and 2019 included 671 VRE cases, of which most (93.4%) consisted of colonization events, 29 (4.3%) infections and 15 (2.2%) bacteremia. Wide adoption of this VRE control guideline seemed to have a positive effect on VRE containment in Swiss acute care hospitals over two years, even if its long-term impact on the VRE epidemiology remains to be evaluated. Broad dissemination and strict implementation of a uniform national guideline may therefore serve as model for other countries to fight VRE epidemics on a national level.
Sections du résumé
BACKGROUND
Vancomycin resistant enterococci (VRE) are on the rise in many European hospitals. In 2018, Switzerland experienced its largest nosocomial VRE outbreak. The national center for infection prevention (Swissnoso) elaborated recommendations for controlling this outbreak and published guidelines to prevent epidemic and endemic VRE spread. The primary goal of this study was to evaluate adherence to this new guideline and its potential impact on the VRE epidemiology in Swiss acute care hospitals.
METHODS
In March 2020, Swissnoso distributed a survey among all Swiss acute care hospitals. The level of adherence as well as changes of infection prevention and control (IPC) strategies in the years 2018 and 2019 after publication of the national guidelines were asked along with an inventory on VRE surveillance and outbreaks.
RESULTS
Data of 97/146 (66%) participants were available, representing 81.6% of all acute care beds operated in Switzerland in 2019. The vast majority-72/81 (88%) responding hospitals-have entirely or largely adopted our new national guideline. 38/51 (74.5%) hospitals which experienced VRE cases were significantly more likely to have changed their IPC strategies than those 19/38 (50%) hospitals without VRE cases p = 0.017). The new IPC guidelines included (1) introduction of targeted admission screening in 89.5%, (2) screening of close contacts of VRE cases in 56%, and (3) contact precaution for suspected VRE cases 58% of these hospitals. 52 (54%) hospitals reported 569 new VRE cases in 2018 including 14 bacteremia, and 472 new cases in 2019 with 10 bacteremia. The ten largest outbreaks encountered between 2018 and 2019 included 671 VRE cases, of which most (93.4%) consisted of colonization events, 29 (4.3%) infections and 15 (2.2%) bacteremia.
CONCLUSION
Wide adoption of this VRE control guideline seemed to have a positive effect on VRE containment in Swiss acute care hospitals over two years, even if its long-term impact on the VRE epidemiology remains to be evaluated. Broad dissemination and strict implementation of a uniform national guideline may therefore serve as model for other countries to fight VRE epidemics on a national level.
Identifiants
pubmed: 35090563
doi: 10.1186/s13756-022-01051-9
pii: 10.1186/s13756-022-01051-9
pmc: PMC8795934
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : P4P4PM_194449
Informations de copyright
© 2022. The Author(s).
Références
J Hosp Infect. 2020 Aug;105(4):726-735
pubmed: 32439548
Dtsch Arztebl Int. 2013 Oct;110(43):725-31
pubmed: 24222791
Antimicrob Agents Chemother. 2002 Jun;46(6):1619-28
pubmed: 12019066
Stat Methods Med Res. 1999 Jun;8(2):135-60
pubmed: 10501650
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Jul;59(7):908-15
pubmed: 27306879
Infection. 2005 Oct;33(5-6):309-13
pubmed: 16258859
Antimicrob Agents Chemother. 2005 Jan;49(1):77-81
pubmed: 15616278
J Hosp Infect. 2021 Oct;116:53-59
pubmed: 34252477
Euro Surveill. 2018 Jul;23(29):
pubmed: 30043725
Antimicrob Resist Infect Control. 2019 Jan 17;8:16
pubmed: 30675343
Antimicrob Resist Infect Control. 2018 Jul 9;7:81
pubmed: 30002821
J Antimicrob Chemother. 2014 May;69(5):1185-92
pubmed: 24458513
mBio. 2013 Aug 13;4(4):
pubmed: 23943759
Antimicrob Resist Infect Control. 2012 Feb 13;1(1):9
pubmed: 22958336
BMJ Qual Saf. 2016 Dec;25(12):986-992
pubmed: 26369893
Antimicrob Resist Infect Control. 2018 Mar 22;7:44
pubmed: 29588851
Rev Med Suisse. 2013 Apr 24;9(383):890-3
pubmed: 23697084
Drug Resist Updat. 2020 Dec;53:100732
pubmed: 33189998
Clin Microbiol Infect. 2019 Jun;25(6):688-695
pubmed: 30287413
J Infect Public Health. 2017 Mar - Apr;10(2):185-190
pubmed: 27140696
Antimicrob Resist Infect Control. 2018 Apr 24;7:54
pubmed: 29760912
Infect Control Hosp Epidemiol. 2008 May;29(5):398-403
pubmed: 18419360
Lancet Infect Dis. 2001 Dec;1(5):314-25
pubmed: 11871804
J Hosp Infect. 2018 Dec;100(4):e216-e225
pubmed: 29475013
Eur J Clin Microbiol Infect Dis. 2019 Jun;38(6):1163-1170
pubmed: 30888549
Antimicrob Resist Infect Control. 2019 Sep 23;8:153
pubmed: 31572571
Infect Control Hosp Epidemiol. 2008 May;29(5):404-9
pubmed: 18419361
J Clin Epidemiol. 2010 Feb;63(2):180-4
pubmed: 19716265
J Antimicrob Chemother. 2015 Sep;70(9):2474-82
pubmed: 26031466